Rocket PharmaceuticalsRCKT
RCKT
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees: 299
0
Funds holding %
of 7,430 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
113% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $485K
68% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 47
12.33% less ownership
Funds ownership: 101.05% [Q1] → 88.72% (-12.33%) [Q2]
18% less funds holding
Funds holding: 235 [Q1] → 192 (-43) [Q2]
49% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 80
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
68% less capital invested
Capital invested by funds: $722M [Q1] → $232M (-$490M) [Q2]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.50
26%
downside
Avg. target
$8.55
151%
upside
High target
$19
459%
upside
10 analyst ratings
7 positive
70%
3 neutral
30%
0 negative
0%
B of A Securities Jason Zemansky | 194%upside $10 | Buy Upgraded | 20 Aug 2025 |
Chardan Capital Geulah Livshits | 224%upside $11 | Buy Maintained | 20 Aug 2025 |
Cantor Fitzgerald Josh Schimmer | 135%upside $8 | Overweight Maintained | 8 Aug 2025 |
Canaccord Genuity Whitney Ijem | 194%upside $10 | Buy Maintained | 25 Jul 2025 |
B of A Securities Greg Harrison | 18%upside $4 | Neutral Downgraded | 25 Jul 2025 |
Financial journalist opinion
Based on 75 articles about RCKT published over the past 30 days
Positive
Zacks Investment Research
4 days ago
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Negative
Barrons
5 days ago
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
The past year has been a disappointing one for gene therapies.
Positive
Benzinga
6 days ago
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
Rocket Pharmaceuticals Inc. RCKT stock is trading higher on Wednesday after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease.
Positive
Reuters
6 days ago
US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial
Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.
Neutral
Business Wire
6 days ago
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. The hold was lifted in under three months, underscoring the efficiency of the FDA's review pr.
Neutral
GlobeNewsWire
2 weeks ago
Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Neutral
Business Wire
2 weeks ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
NEW YORK--(BUSINESS WIRE)---- $RCKT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Neutral
PRNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Neutral
PRNewsWire
2 weeks ago
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
2 weeks ago
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK , Aug. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the "Class Period"), of the important August 11, 2025 lead plaintiff deadline. So what: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Charts implemented using Lightweight Charts™